Skip to main content
. 2019 Apr 24;10:879. doi: 10.3389/fimmu.2019.00879

Figure 8.

Figure 8

Blocking of OX40-OX40L axis inhibits NK cell proliferation. (A) Freshly prepared PBMCs were co-cultured with γ-irradiated K562-OX40L feeder cells in the presence of 10 U/mL of IL-2 for 3 days and NK cells were isolated to 0.1 × 105 NK cells/well with 100 U/mL of IL-2 and IgG or Oxelumab in flat-bottom or round-bottom wells in 96-well plates. (B,C) CFSE dilution assay was performed every 2 days in flat or round-bottom wells. Data are representative of three independent experiments. (D) The purity and (E) fold expansion of expanded NK cells in human IgG (orange dots) and Oxelumab (green squares) treated group were measured. OX40L blocking antibodies (Oxelumab) were added at day 3 when OX40L expression was peaked. Purities and fold expansion in two groups significantly different from day 14 and day 21 of culture, respectively. (hIgG treated group, n = 3; and Oxelumab treated group, n = 5; error bars, mean ± SD; ns, not significant; *p < 0.05).